3,4-dihydroxyphenylacetic acid has been researched along with Vomiting in 2 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In an attempt to clarify the mechanisms of emesis induced by cytotoxic drugs, we measured kaolin ingestion (pica) and the tissue concentrations of 5-HT, norepinephrine (NE) and dopamine in various brain regions of rats after cisplatin administration." | 3.72 | 5-hydroxytryptamine (5-HT) concentrations in the hippocampus, the hypothalamus and the medulla oblongata related to cisplatin-induced pica of rats. ( Endo, T; Hamaue, N; Hirafuji, M; Liu, Y; Minami, M, 2003) |
| " However, in contrast to D2-selective antagonists, SCH39166 failed to increase plasma prolactin levels, did not block apomorphine-induced emesis in the dog and had minimal effects on the striatal levels of homovanillic acid or dihydroxyphenylacetic acid." | 3.67 | Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. ( Barnett, A; Berger, JG; Chipkin, RE; Coffin, VL; Iorio, LC; McQuade, RD, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Hamaue, N | 1 |
| Endo, T | 1 |
| Hirafuji, M | 1 |
| Minami, M | 1 |
| Chipkin, RE | 1 |
| Iorio, LC | 1 |
| Coffin, VL | 1 |
| McQuade, RD | 1 |
| Berger, JG | 1 |
| Barnett, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ecopipam Treatment of Tourette Syndrome[NCT01244633] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Safety and Pilot Activity Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease[NCT01065558] | Phase 1 | 5 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Yale Global Tic Severity Score is a composite of subject reported severity of motor (range 0-25) and vocal (range 0-25) tics , as well as an impairment score (range 0-50). The outcome we are using is the Total Tic Severity score which is the sum of the motor and vocal tic severity scores (range 0-50). The higher the score on this scale, the more severe the symptoms. A positive drug effect is associated with a decrease from baseline. (NCT01244633)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ecopipam | 25.3 |
Change in the self-injurious subscale of the Behavior Problems Inventory (BPI). the BPI is a well-validate test to evaluate the frequency and severity of a patient's self-injurious behavior. Values range from 0 to 50, and a low score means few/less severe behaviors (NCT01065558)
Timeframe: Screening visit and end of study (two weeks)
| Intervention | Change in BPI score (Mean) |
|---|---|
| Ecopipam Treated Patients | 22.5 |
This study's primary outcome is the safety of ecopipam in Lesch-Nyhan patients as measured by standard clinical laboratory tests. The patients will also be observed and questioned about other side effects, such as whether they feel more or less tired.Standard clinical laboratory tests for liver, kidney and blood function were conducted. The normal ranges for each of these tests were different and are too numerous to be individually listed here. However, if any individual value were to be either three-times greater or lesser than the upper or the lower limit of the test, then that value was considered to have been changed. (NCT01065558)
Timeframe: Two weeks
| Intervention | Participants (Number) |
|---|---|
| Ecopipam Treated Patients | 0 |
2 other studies available for 3,4-dihydroxyphenylacetic acid and Vomiting
| Article | Year |
|---|---|
5-hydroxytryptamine (5-HT) concentrations in the hippocampus, the hypothalamus and the medulla oblongata related to cisplatin-induced pica of rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antineoplastic Agents; Brain; Cisplatin; Dopamine; Hydroxyi | 2003 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |